Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Inflammatory breast cancer (IBC) is a rare and highly aggressive subtype of breast cancer that poses significant clinical challenges. At Alfa Cytology, our team of experienced biologists work with you to develop IBC therapeutics.
Accounting for only 2-4% of all breast cancer cases, IBC is characterized by its rapid onset, propensity for locoregional recurrence, and dismal prognosis. Unlike its non-inflammatory counterparts, IBC often presents with distinct skin changes, such as erythema, edema, and peau d'orange appearance, which are the result of extensive dermal lymphatic invasion by tumor cells.
Fig.1 Update on systemic treatment for inflammatory breast cancer. (Chainitikun S., et al. 2020)
Emerging evidence suggests that the unique tumor microenvironment (TME) of IBC, characterized by extensive lymphovascular invasion, immune dysfunction, and aberrant angiogenesis, plays a pivotal role in driving aggressive disease progression.
Our preclinical studies have identified several promising molecular targets within the IBC TME, including components of the lymphangiogenic and angiogenic signaling cascades, as well as key immune checkpoint regulators.
| Identifier | Targets | Therapeutics | Phase |
| NCT05041101 | Anti-inflammatory Drug + Microtubule Inhibitor | Grapiprant and Eribulin | |
| NCT03202316 | PD-L1 Antibody + Kinase Inhibitors + Microtubule Inhibitor | Atezolizumab + Cobimetinib + Eribulin | |
| NCT01036087 | Anti-EGFR Antibody + Mitotic Inhibitor + Cytostatics | Panitumumab + Nab-paclitaxel + Carboplatin | |
| NCT00105950 | Anti-HER Small Molecule | Lapatinib |
Inflammatory breast cancer is a relatively rare disease but malignant. Multiple factors influence prognosis and therapy options. Therefore, Alfa Cytology is working on providing one-stop solutions for inflammatory breast cancer, including but not limited to the following.
At Alfa Cytology, we recognize the critical importance of robust preclinical models in the development of effective therapies for IBC. Given the unique biological features and aggressive nature of this disease, we have established a comprehensive suite of in vitro and in vivo modeling services to support our drug discovery and translational research efforts.
| IBC Cell Lines | Animal Models of IBC |
|
|
|
|
Alfa Cytology is committed to the research and study of IBC, from molecular biology services, and cancer biomarker discovery services, to preclinical research services, providing one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for IBC. If you are interested in our service, please contact us.
Reference
